Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results